This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Managing diarrhoea with dose reduction and treatment interruption

Prescribing Information and SmPC (Great Britain) & Prescribing Information and SmPC (Northern Ireland) [External links]

Favourable risk

Case study summary

Prof. Tom Powles, Clinical Professor of Genitourinary Oncology at Barts Cancer Centre presents a case study of a 72 year old male with advanced Renal Cell Carcinoma, treated with KEYTRUDA® (pembrolizumab) in combination with axitinib. Following a nephrectomy for G2 T3 clear cell renal cancer, the patient developed a number of lung lesions. Prof Tom Powles, describes his treatment decisions, and management of the patient for adverse events including grade 1 diarrhoea.

Favourable
72
Male
1
Heavy smoker, osteoarthritis, controlled hypertension

Supporting documentation

Prescribing Information and SmPC (Great Britain) & Prescribing Information and SmPC (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-RCC-00251 | Date of Preparation: November 2020